JD.com enters its Q2 earnings report today with one of the sharpest short-covering moves of recent months already underway — the real question heading into the release is whether the bears were right to leave, or whether they jumped too soon.
Short sellers have been retreating aggressively from JD. Estimated short interest has collapsed by roughly 30% in a single week and nearly 38% over the past month, falling from around 34 million shares in early July to just under 21 million now. The ORTEX short score has dropped from above 52 to 41 in two weeks — a decisive move away from bearish territory. Borrow conditions confirm there is no pressure forcing the exit: cost to borrow is a negligible 0.45%, and availability has opened up dramatically, with roughly 3.3 shares available in the lending pool for every one already borrowed. That is well above recent norms — availability was near parity with short interest as recently as late July, and has since eased considerably. Shorts are leaving because they want to, not because they are being squeezed.
The price action tells a more complicated story. Despite the covering, JD fell 7.3% yesterday and is down more than 10% on the week, trading at $29.30. The stock is broadly weaker alongside its peer group — fell 2.1% on the day, dropped 3.6%, and slid nearly 6% — suggesting macro pressure on Chinese consumer names rather than company-specific deterioration. Options positioning is essentially neutral: the put/call ratio of 0.69 sits almost exactly on its 20-day average, with a z-score near zero. Options traders are neither hedging into the print nor leaning bullish; they have largely priced in the uncertainty and moved on.
The analytical debate centres on whether JD can sustain revenue momentum without destroying its margin. The bull case is straightforward — 15.8% year-over-year revenue growth, supermarket gains outpacing expectations, and forward earnings estimates that have been revised upward. JD ranks in the 95th percentile on EPS surprise quality. Barclays maintained an Overweight rating in mid-July, trimming its target modestly from $43 to $41 — still well above the current price. The bear case is margin erosion: heavy subsidies and thin order economics have already pushed net margin forecasts down to 3.9–4.0% through FY26. The stock's EV/EBITDA has eased roughly 3% over the past month as the price has retreated, but at under 5x, the valuation is not stretched — it may simply reflect persistent skepticism about whether profitability ever arrives at scale. It is worth noting that the consensus mean price target of $267 appears inconsistent with the current price and recent analyst targets in the $35–$43 range; that aggregate figure likely reflects stale or differently-denominated data and should be disregarded.
One previous print offers a useful data point: after JD's May 2026 Q1 results, the stock fell 5.2% on the day and 6.8% over the five following sessions — a reaction that preceded the current slide. Founder Richard Liu received an award of one million shares in mid-May, but insider cash activity has been minimal, with the CEO and CFO selling only token amounts in early July following routine compensation awards.
Today's print tests whether the revenue engine can keep firing while the subsidy-driven cost structure starts to normalise — and whether the short sellers who covered into weakness made the right call.
See the live data behind this article on ORTEX.
Open JD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
